Compare FIBK & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | CNTA |
|---|---|---|
| Founded | 1879 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 6.1B |
| IPO Year | 1997 | 2021 |
| Metric | FIBK | CNTA |
|---|---|---|
| Price | $34.08 | $39.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $35.63 | ★ $42.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.5M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 34.25 | 29.13 |
| EPS | ★ 2.94 | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $11.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.76 | $10.95 |
| 52 Week High | $39.26 | $40.26 |
| Indicator | FIBK | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 75.84 |
| Support Level | $31.37 | $24.80 |
| Resistance Level | $34.10 | $40.26 |
| Average True Range (ATR) | 0.70 | 0.69 |
| MACD | 0.21 | 0.28 |
| Stochastic Oscillator | 68.52 | 94.90 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.